BR112021021838A8 - Método para tratar dor associada à endometriose com uso de composto de diaminopirimidina - Google Patents

Método para tratar dor associada à endometriose com uso de composto de diaminopirimidina

Info

Publication number
BR112021021838A8
BR112021021838A8 BR112021021838A BR112021021838A BR112021021838A8 BR 112021021838 A8 BR112021021838 A8 BR 112021021838A8 BR 112021021838 A BR112021021838 A BR 112021021838A BR 112021021838 A BR112021021838 A BR 112021021838A BR 112021021838 A8 BR112021021838 A8 BR 112021021838A8
Authority
BR
Brazil
Prior art keywords
endometriosis
pain associated
treatment
compound
diaminopyrimidine
Prior art date
Application number
BR112021021838A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112021021838A2 (pt
Inventor
Zhao Yanping
Huang Huai
Wang Hongjun
Jiang Yuanyuan
Liang Huining
An Ran
Lan Zhou
Wang Jin
Zhou Liying
Liu Yanan
Original Assignee
Beijing Tide Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beijing Tide Pharmaceutical Co Ltd filed Critical Beijing Tide Pharmaceutical Co Ltd
Publication of BR112021021838A2 publication Critical patent/BR112021021838A2/pt
Publication of BR112021021838A8 publication Critical patent/BR112021021838A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR112021021838A 2019-04-30 2020-04-29 Método para tratar dor associada à endometriose com uso de composto de diaminopirimidina BR112021021838A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2019085209 2019-04-30
PCT/CN2020/087689 WO2020221277A1 (zh) 2019-04-30 2020-04-29 二氨基嘧啶类化合物治疗子宫内膜异位相关的疼痛的方法

Publications (2)

Publication Number Publication Date
BR112021021838A2 BR112021021838A2 (pt) 2022-01-04
BR112021021838A8 true BR112021021838A8 (pt) 2023-02-28

Family

ID=73028778

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021021838A BR112021021838A8 (pt) 2019-04-30 2020-04-29 Método para tratar dor associada à endometriose com uso de composto de diaminopirimidina

Country Status (12)

Country Link
US (1) US12605381B2 (https=)
EP (1) EP3960178B1 (https=)
JP (1) JP7663508B2 (https=)
KR (1) KR102935431B1 (https=)
CN (1) CN114007620B (https=)
AU (1) AU2020266947B2 (https=)
BR (1) BR112021021838A8 (https=)
CA (1) CA3138238A1 (https=)
MX (1) MX2021013347A (https=)
SG (1) SG11202111960PA (https=)
TW (1) TWI737285B (https=)
WO (1) WO2020221277A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117186068A (zh) * 2017-11-01 2023-12-08 北京泰德制药股份有限公司 P2x3和/或p2x2/3受体拮抗剂、包含其的药物组合物及其用途
WO2023081800A1 (en) * 2021-11-05 2023-05-11 The Regents Of The University Of California Alpha-2a adrenergic receptor modulators and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008104474A1 (en) * 2007-02-28 2008-09-04 F. Hoffmann-La Roche Ag Diaminopyrimidines
WO2017160569A1 (en) 2016-03-14 2017-09-21 Afferent Pharmaceuticals Inc. Pyrimidines and variants thereof, and uses therefor
AU2017237929B2 (en) * 2016-03-25 2021-04-15 Afferent Pharmaceuticals Inc. Pyrimidines and variants thereof, and uses therefor
CN117186068A (zh) * 2017-11-01 2023-12-08 北京泰德制药股份有限公司 P2x3和/或p2x2/3受体拮抗剂、包含其的药物组合物及其用途

Also Published As

Publication number Publication date
WO2020221277A1 (zh) 2020-11-05
KR102935431B1 (ko) 2026-03-05
JP7663508B2 (ja) 2025-04-16
MX2021013347A (es) 2022-01-24
CN114007620A (zh) 2022-02-01
CA3138238A1 (en) 2020-11-05
AU2020266947B2 (en) 2025-10-09
SG11202111960PA (en) 2021-12-30
BR112021021838A2 (pt) 2022-01-04
US12605381B2 (en) 2026-04-21
JP2022531570A (ja) 2022-07-07
AU2020266947A1 (en) 2021-12-16
KR20220008286A (ko) 2022-01-20
EP3960178A1 (en) 2022-03-02
US20220249478A1 (en) 2022-08-11
TW202106303A (zh) 2021-02-16
TWI737285B (zh) 2021-08-21
CN114007620B (zh) 2024-08-06
EP3960178B1 (en) 2026-03-18
EP3960178A4 (en) 2023-01-25

Similar Documents

Publication Publication Date Title
BR112021017354A2 (pt) Método para o tratamento de doença hepática adiposa e/ou esteatoepatite
MX2024004332A (es) Metodos de uso de inhibidores de ehmt2 para tratar o prevenir transtornos sanguíneos.
BR112021026214A2 (pt) Método para tratamento de fibrose pulmonar idiopática
ZA202204929B (en) Rimegepant for cgrp related disorders
EA202090955A1 (ru) Способы применения ингибиторов ehmt2 в лечении или предупреждении нарушений со стороны крови
BR112015022197A8 (pt) uso de um composto para fabricação de um medicamento ou composição farmacêutica para o tratamento de cataplexia
BR112018005454A2 (pt) administração de potencializadores de cftr deuterados
CL2018002727A1 (es) Medicina obtenida mediante la combinación de agonista fxr y arb
BR112014004741A2 (pt) pelo menos uma entidade química; composição farmacêutica; uso de uma quantidade terapeuticamente eficaz de pelo menos uma entidade química; composição farmacêutica embalada
BR112022000231A2 (pt) Novos métodos
BR112016015236A8 (pt) composto,composição farmacêutica,uso de um composto,método de inibição e método para tratar ou aliviar a gravidade de uma doença.
BR112015021371A2 (pt) uso de agonistas de receptor de formil peptídeo 2 para tratar doenças inflamatórias oculares
BR112022009209A2 (pt) Derivado de amida e método de preparação e uso do mesmo na medicina
EA201691454A1 (ru) Композиции придопидина модифицированного высвобождения
BR112015009037A2 (pt) composição farmacêutica para uso no tratamento de infarto do miocárdio e uso de um peptídeo de fragmento de hmgb1
BR112017016087A2 (pt) formulações para coxim articular adiposo e métodos de uso das mesmas
BR112015022650A2 (pt) inibidores de cinase induzível por sal macrocíclico
BR112021021838A8 (pt) Método para tratar dor associada à endometriose com uso de composto de diaminopirimidina
PH12022550441A1 (en) Azaheteroaryl compound and application thereof
PE20181332A1 (es) Metodos de sedacion y formulacion parenteral para uso durante el tratamiento de cuidados criticos
BRPI0807940B8 (pt) usos de ácido 3´-{n´-[1-(3,4-dimetilfenil)-3-metil-5-oxo-1,5-diidropirazol-4-ilideno]-hidrazino}-2´-hidroxibifenil-3-carboxílico e/ou de um sal farmaceuticamente aceitável do mesmo para o tratamento de câncer e de uma síndrome pré-cancerosa e composição farmacêutica que compreende dito ácido
BR112022008677A2 (pt) Terapia de combinação com 2-(4-clorofenil)-n-((2-(2,6-dioxopiperidina-3-il)-1-oxoisoindolin-5-il) metil)-2,2-difluoroacetamida
BR112017015744A2 (pt) composto apresentando uma estrutura de fórmula (i), um sal farmaceuticamente aceitável do mesmo ou um isômero ótico do mesmo, composição farmacêutica e uso do composto de fórmula (i) para o tratamento e prevenção de mycobacterium tuberculosis ou outras infecções microbianas
MX2021009539A (es) Derivado del profarmaco 6-oxo-1,6-dihidropiridazina, metodo de preparacion del mismo y aplicacion del mismo en medicina.
BR112012020060B8 (pt) uso de n-((1-((4-hidroxitetrahidro-2h-piran-4-il)metil)piperidin-4-il)metil)-3-isopropil-2-oxo-2,3-dihidro-1h-benzo[d]imidazol-1-carboxamida para tratar doença de alzheimer e demência

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]